

1 **Characterization of *Staphylococcus aureus* strains involved in human**
2 **and bovine mastitis**

3 Susana Delgado^{*1,2}, Pilar García², Leonides Fernández¹, Esther Jiménez¹, Mercedes
4 Rodríguez-Baños³, Rosa del Campo³, Juan M. Rodríguez¹.

5 ¹Dpt. Nutrición, Bromatología y Tecnología de los Alimentos. Universidad
6 Complutense de Madrid, 28040 Madrid, ²Instituto de Productos Lácteos de Asturias
7 (IPLA-CSIC), 33300 Villaviciosa Asturias, ³Servicio de Microbiología. Hospital
8 Universitario Ramón y Cajal, 28034 Madrid, Spain.

9

10 *Corresponding author: Dra. Susana Delgado Palacio. Instituto de Productos Lácteos de
11 Asturias Consejo Superior de Investigaciones Científicas (IPLA-CSIC), Carretera de
12 Infiesto s/n 33300 Villaviciosa, Asturias, Spain. Phone: + 34-985892131. Fax: + 34-
13 989892233. E-mail: sdelgado@ipla.csic.es

14

15 Keywords: *Staphylococcus aureus*, mastitis, MLST, genotyping, virulence, antibiotic
16 resistance.

17

18 Running title: *Staphylococcus aureus* from human mastitis infections

19

20

21 **Abstract**

22 *Staphylococcus aureus* is one of the main etiological agents of mastitis in different
23 mammalian species. At present, it is unknown if strains isolated from human mastitis
24 cases share phenotypic properties and genetic background with those obtained from
25 animal mastitis cases. Therefore, the objective of this study was to characterize *S.*
26 *aureus* strains isolated from women with lactational mastitis and to compare them with
27 strains responsible for bovine mastitis and non-infectious strains. All the strains were
28 genotyped by both Pulsed Field Gel Electrophoresis (PFGE) and Multilocus sequence
29 typing (MLST) and submitted to a characterization scheme that included diverse assays
30 related to pathogenic potential and antibiotic resistance. Apart from siderophore
31 production, no significant association was observed between the strains from bovine
32 and human mastitis. Statistical differences between human- and bovine-mastitis
33 associated strains were detected for some traits and virulence determinants; such as the
34 presence of prophages and *cna* and *hly* genes, which were more frequently found within
35 the bovine group. On the contrary, resistance to penicillin was significantly higher
36 among strains isolated from human lactational mastitis, probably related to the common
37 presence of the *blaZ* gene. A high genetic diversity was found among the strains
38 involved in mastitis in breastfeeding women.

39

40 **Introduction**

41 Mastitis is the inflammation of the mammary gland mainly due to a bacterial
42 infection and it is characterized by a variety of local and systemic symptoms. In
43 Veterinary Medicine, the number of studies dealing with the distribution and
44 characterization of the bacterial species involved in mastitis is considerable (Vasudevan
45 *et al.*, 2003; Fueyo *et al.*, 2005; Smith *et al.*, 2005; Kozytska *et al.*, 2010). In contrast,
46 scientific articles on the bacteria causing infectious mastitis in lactating women are
47 scarce and most are, at least, 10 years old (Foxman *et al.*, 2002). However, this
48 condition is relatively common since its incidence oscillates between 5 and 33% of
49 lactating mothers (WHO, 2000; Foxman *et al.*, 2002). *Staphylococcus aureus* (Thomsen
50 *et al.*, 1983; Riordan & Nichols, 1990) and coagulase-negative staphylococci (Delgado
51 *et al.*, 2009) are among the most common etiological agents although, unfortunately,
52 microbiological analysis of human milk and characterization of the strains involved in
53 human mastitis are exceptional.

54 *S. aureus* can express a wide array of potential virulence factors, including surface
55 proteins that promote adherence to damaged tissue, and/or exotoxins and enzymes than
56 can cause a variety of infections in skin and soft tissues, including intramammary
57 mastitis (Iwatsuki *et al.*, 2006). Some evidence suggests that biofilm formation can be a
58 virulence factor associated with *S. aureus* mastitis (Vasudevan *et al.*, 2003).
59 Furthermore, this microorganism can display resistance to several relevant antibiotics,
60 making its eradication difficult (Casey *et al.*, 2007).

61 Common genotypes of *S. aureus* causing mastitis in different ruminants have been
62 described suggesting potential tissue specificity (Mørk *et al.*, 2005; Aires de Sousa *et al.*,
63 2007). However, different genetic clusters and lineages among strains isolated from
64 samples of human and bovine origin have been reported (Zadoks *et al.*, 2000; van

65 Leeuwen *et al.*, 2005), which point to the concept of host specialization (Herron-Olson
66 *et al.*, 2007; Sung *et al.*, 2008). In humans, most infections caused by *S. aureus* seem to
67 derive by own carriage strains (Wertheim *et al.*, 2005). The potential virulence factors
68 possessed by the *S. aureus* strains associated with human mastitis remain still
69 undescribed. The objective of this work was to assess and compare the presence of
70 pathogenic traits among a number of strains of *S. aureus* isolated from both women and
71 cows suffering lactational mastitis, alongside some non-infectious strains, by a variety
72 of geno- and phenotypic assays.

73

74 **Material and methods**

75 ***S. aureus* strains and growth conditions**

76 Twenty strains of *S. aureus* isolated from cases of infectious mastitis were included
77 in this study. Among them, 10 were isolated from breast milk of women suffering
78 mastitis (OD111, S3B, ACLI1, S1LI12, DH3a, DI2e, BALD1, O2LI2, Z2LD1 and
79 AXLI12; Delgado *et al.*, 2008) while the remaining 10 were isolated from milk of dairy
80 cows with clinical mastitis in Asturias, Spain (SA1, SA3, SA4, SA5, SA8, SA10, SA11,
81 SA14, SA15 and SA16; García *et al.*, 2009). In addition, 10 strains with a non-clinical
82 origin were also included for comparative purposes: five from breast milk of healthy
83 women (LC001, LG5081, LX153b, L1741 and L1744; Jiménez *et al.*, 2008) and five
84 from bulk tank milk (GDC3, GDC6, AC11, JFL2 and GRA16; García *et al.*, 2009). Five
85 *S. aureus* strains (CECT 435, CECT 957, CECT 976, CECT 4013, and CECT 4439)
86 from the Spanish Culture Collection were used as controls in the different assays. The
87 isolates were routinely grown in liquid and agarized Brain Heart Infusion (Oxoid,
88 Basingstoke, UK) at 37 °C for 24 h and their identity was confirmed on the basis of
89 different microbiological and biochemical tests (shape, Gram-staining, catalase and

90 coagulase activities) and PCR sequencing of *tuf* (Martineau *et al.*, 2001), and 16S rRNA
91 genes using primers pbl16 (5'-AGAGTTTGATCCTGGCTCA-3') and mlb16 (5'-
92 GGCTGCTGGCACGTAGTTAG-3') (Kullen *et al.*, 2000).

93

94 **Genotyping of the isolates by Pulsed field gel electrophoresis (PFGE) and** 95 **Multilocus sequence typing (MLST)**

96 **All** isolates were submitted to PFGE genotyping according to the protocol of
97 Murchan *et al.* (2003). Chromosomal DNA was digested with the endonuclease *Sma*I
98 (New England Biolabs, Ipswich, USA) at 37 °C for 16 h. Then, electrophoresis was
99 carried out in a CHEF DR-III apparatus (Bio-Rad Laboratories, Hercules, USA) for 23
100 h at 14 °C at 6 V cm⁻¹ with pulses from 5 to 50 s. A standard pattern (Lambda Ladder
101 PFG Marker, New England Biolabs) was included in the gels to allow comparison of
102 the digitally normalized PFGE profiles. **Gels were analyzed with Phoretix 5.0 software**
103 **(Nonlinear Dynamics Ltd., United Kingdom) using Dice's coefficient to perform the**
104 **cluster analysis of the PFGE patterns.**

105 MLST was carried out as previously described **by** Enright *et al.* (2000). The method
106 involves the amplification by PCR of seven housekeeping genes (*arcC*, *aroE*, *glpF*, *gmk*,
107 *pta*, *tpi* and *yqiL*) following sequencing, and each unique sequence defines an allele.

108 **Bacterial genomic DNA used for the PCR reactions was obtained from pure cultures**
109 **with the DNeasy tissue kit (QIAGEN, Hilden, Germany). The resulting sequences were**
110 **trimmed, aligned and** compared to the allele sequences in the *S. aureus* MLST database
111 (<http://saureus.mlst.net/>), and each allelic profile was assigned to a sequence type (ST).
112 All of them were submitted to the database and registered under identity numbers 3193
113 to 3220. The STs **were clustered into clonal complexes (CCs)** by using the eBURST
114 algorithm (www.eburst.mlst.net).

115

116 **Detection of genes encoding toxins, adhesins and other virulence determinants**

117 The presence of different toxins, adhesins and other virulence factors, including
118 some antibiotic resistance genes, was screened by PCR using the primers described in
119 Table 1. For the detection of the four hemolysin genes (*hla*, *hly*, *hlg*, *hld*) a multiplex
120 PCR method was developed with the following conditions: 1 cycle of 95 °C for 5 min,
121 30 cycles of 95 °C for 1 min, 58 °C for 1 min, and 72 °C for 2 min, and a final
122 extension of 72 °C for 10 min. The genes encoding four adhesins (*fnbA*, *clfa*, *sdrE*, *ebpS*)
123 were detected by multiplex PCR. The PCR program consisted of 1 cycle of 95 °C for 5
124 min, 30 cycles of 95 °C for 1 min, 50 °C for 1 min, and 72 °C for 2 min, and a final
125 extension of 72 °C for 10 min. Each multiplex PCR reaction mixture consisted of 3 mM
126 MgCl₂, 1.5X *Taq* buffer, 4 mM each dNTP, 2.5 U *EcoTaq* polymerase (Ecogen,
127 Barcelona, Spain), 10 μM of each primer and 1.5 μl of purified DNA. Single PCR
128 reactions were used for screening the rest of the genes with standard concentrations of
129 the components in the mixtures and the conditions originally described (Table 1). The
130 use of different annealing temperatures in these reactions is specified in Table 1.

131

132 **Determination of minimal inhibitory concentrations (MICs) to antibiotics**

133 The determination of the MICs to several antibiotics commonly used against
134 staphylococcal infections was performed by a microdilution method using the Sensititre
135 plates Staenc1F (Trek Diagnostic Systems, Cleveland, USA) following the
136 manufacturer's instructions. The antibiotics analyzed were: penicillin, ampicillin,
137 amoxicillin-clavulanic acid, teicoplanin, chloramphenicol, erythromycin, mupirocin,
138 streptomycin, gentamicin, clindamycin, oxacillin, ciprofloxacin, fosfomicin, imipenem,

139 nitrofurantoin, trimethoprim-sufamethoxazole, tetracycline, vancomycin, linezolid,
140 quinupristin-dalfoprisicin, and rifampin.

141

142 **Phenotypic assays**

143 **a) Determination of hemolytic activity.** Hemolytic activity was assayed on
144 Columbia agar plates supplemented with 5% sheep blood (bioMérieux, Marcy l'Etoile,
145 France) following the procedure of Freney *et al.* (1999). After an incubation of 72 h at
146 37 °C, plates were analyzed and the strains were considered hemolytic if complete lysis
147 of the red blood cells surrounding the colony **was observed** (halo ~1.5 mm).

148 **b) Slime production.** The ability of the isolates to form slime was assessed using
149 the Congo Red Agar assay (Freeman *et al.*, 1989). The plates were incubated at 37 °C
150 for 24 h followed by additional storage at room temperature 24 h. Isolates displaying
151 rough black colonies were considered as slime producers while those showing red
152 colonies were negative.

153 **c) Biofilm formation ability.** Biofilm formation was assayed using a microtiter
154 plate assay as described Vasudevan *et al.* (2003) with some modifications. Strains were
155 grown in Brain Heart Infusion and the cultures were diluted 1:200 in Tryptic Soy Broth
156 (Oxoid) supplemented with 0.25% glucose. Aliquots of 200 µl of each dilution were
157 placed into 96-well “U” bottom polystyrene microtiter plates and incubated for 18 h at
158 37 °C. The wells were washed three times with 300 µl of sterile phosphate-buffered
159 saline (pH 7.2) and let dried at room temperature. Afterwards, **25 µl of a 1%** crystal
160 violet solution was added to the wells for biofilm staining and the plates were incubated
161 for 15 min at room temperature. Microtiter plates were washed by fully immersing in
162 water and allowed to dry in inverted position. **Bounded crystal violet was** solubilized in
163 200 µl of ethanol (95% v/v), and 125 µl were transferred to another plate to measure the

164 optical density (OD) of each well at 570 nm using a MicroELISA Auto Reader
165 (Labsystems, Helsinki, Finland). Each strain was tested in triplicate and a known
166 biofilm-producer strain (*S. aureus* CECT 4013) was included as a positive control in all
167 assays. The biofilm assays were performed on duplicate.

168 **d) Lysogeny determination.** The presence of resident prophages in the *S. aureus*
169 strains was checked after mitomycin C induction. Mid-exponential phase cultures were
170 obtained for each strain and mitomycin C (Sigma-Aldrich, St. Louis, USA) was added
171 at a concentration of 0.5 $\mu\text{g ml}^{-1}$. Samples were incubated for 4 h at 37 °C and
172 supernatants filtered and subjected to plaque assay. Each supernatant was tested against
173 all strains. Aliquots (0.1 ml) of stationary-phase host cultures were mixed with
174 appropriate dilutions of individual phage suspensions in 5 ml of molten 2xTY top agar
175 (0.7% agar) and the mixture was poured on 2xTY agar plates (Sambrook *et al.*, 1989).

176 **e) Siderophore production.** The siderophore production in liquid culture was
177 performed following the methodology previously used by Massonet *et al.* (2006) with
178 some modifications. For the growth of the strains, the RPMI 1640 medium (Sigma) was
179 used. Iron was removed from the RPMI medium by overnight batch incubation with 6%
180 (w/v) sterile Chelex 100 (Sigma) at room temperature. To avoid the reduction in the
181 calcium and magnesium levels by the chelating effect of Chelex, the medium was
182 afterwards enriched with filter sterilized solutions of CaCl_2 (0.07 mM) and MgSO_4 (0.7
183 mM). *S. aureus* strains were inoculated in the iron-depleted medium and incubated for
184 24 h at 37 °C in an orbital shaker. Then, the strains were subcultured (1%) in the same
185 medium and incubated under the same conditions for 48 h. Cultures were centrifuged at
186 $16,000 \times g$ for 5 min and the supernatants were assayed for siderophore production.
187 Siderophore production was measured with the Chrome Azurol S liquid assay as
188 described by Schwyn and Neilands (1987). Briefly, 500 μl of supernatant were mixed

189 with 500 µl of Chrome Azurol S solution and 10 µl of shuttle solution (0.2 M 5'-
190 sulfosalicylic acid) were added to the mixture. After 15 min of incubation at room
191 temperature the absorbance at 630 nm was measured. The percentage of siderophore
192 units was calculated as follows: $[(Ab-As)/Ab] \times 100$, being Ab the absorbance of the
193 non-inoculated medium and As the absorbance of the samples.

194

195 **Statistical analysis**

196 The distribution of putative virulence genes, antibiotic resistance, hemolysis, slime
197 production and lysogeny among the *S. aureus* strains from different hosts (human and
198 bovine) with mastitic infection and/or from mastitis-associated and non-infectious
199 strains was compared using two-tailed Fisher's exact test. The non-parametric Kruskal
200 Wallis test was used to compare the biofilm forming ability between strains isolated
201 from bovine and human mastitis cases and the siderophore production observed in
202 mastitis and non-infectious strains. Differences between groups were considered
203 statistically significant if *P* values were ≤ 0.05 . Statistical analysis was performed with
204 the SPSS statistical package (SPSS Inc., Chicago, USA).

205

206 **Results and Discussion**

207 **Genetic diversity.** Twenty strains of *S. aureus* from mastitis (10 from human and
208 10 from bovine cases) and 10 strains that were not involved in infections (five from
209 breast milk of healthy women and five from bulk tank milk) were included in the study.

210 Except for GRA16 and AC11 isolates from bulk tank milk, all the strains could be
211 individually distinguished by PFGE genotyping since each strain generated a different
212 band pattern. Three main clusters were observed in the dendrogram obtained by
213 computer assisted analysis (Fig. 1). Clustering of the strains was not apparently based

214 on the host or pathogenic origin. Strains from human mastitis were distributed along the
215 three clusters and showed diverse genotypes. On the contrary, most of the isolates from
216 bovine mastitis (8 out of 10) showed closely-related pulsotypes and grouped together in
217 the same cluster. The existence of common or similar genotypes among *S. aureus*
218 isolated from bovine mastitis has been previously reported and could reflect a long-term
219 persistence into the bovine mammary gland (Anderson & Lyman, 2006). The strains
220 were also typed by MLST analysis, and the results were in accordance with those
221 obtained by PFGE (Fig. 1) even though different pulsotypes were observed within
222 strains grouped in the same ST. Seven out the 10 isolates causing bovine mastitis
223 grouped into ST97/ST352-CC97 and two strains were related to ST151. These lineages
224 are rather prevalent among bovine mastitis isolates from different countries (Smith *et al.*,
225 2005; Herron-Olson *et al.*, 2007; Rabello *et al.*, 2007; Sung *et al.*, 2008) and seem to be
226 adapted, not only to the mammary gland, but also to the bovine environment. This
227 adaptation would explain their presence also among the strains obtained from bulk tank
228 milk. Human mastitis strains presented higher diversity than the bovine ones belonging
229 up to 7 different CCs, including the newly described ST1598-CC154 and the singleton
230 ST1597. Some strains of human origin, including those isolated from healthy women,
231 belong to CC5 and CC30. These clonal complexes have previously been related to *S.*
232 *aureus* infections in humans but were also associated to asymptomatic human carriers
233 (Wertheim *et al.*, 2005; Rabello *et al.*, 2007; Sakwinska *et al.*, 2009). This could
234 indicate that some *S. aureus* mastitis infections in breastfeeding women may derive by
235 own carriage strains and host predisposal factors might be also important in the
236 development of lactational mastitis.
237

238 **Presence of potential virulence genes.** Multiple properties of *S. aureus* contribute
239 to its virulence. In this study, the presence of 18 genes encoding a variety of potential
240 virulence factors was determined by PCR (Fig. 2), and the results are shown in Table 2.
241 Statistical analysis was only applied to 11 out of the 18 genes, since *hla*, *hld*, *fnbA*, *clfA*,
242 *icaA* were present in all the strains and *pvl-S/F*, *se-adej* were absent in all of them.
243 Significant differences between strains isolated from human and bovine cases of
244 infectious mastitis were observed for two genes; *cna* and *hly* genes, encoding a collagen
245 adhesin and the β -hemolysin, respectively, that were more common in the bovine than
246 in the human group (10/5 strains, Fisher's exact test $P = 0.033$, for *cna* gene and 8/1
247 strains, Fisher's exact test $P = 0.006$, for *hly* gene). No significant differences were
248 observed in the rest of tested genes, even though the occurrence of *bla_Z* gene (encoding
249 resistance to β -lactams antibiotics) was higher among the human strains (9 versus 4
250 strains, $P = 0.057$). Pyrogenic toxin superantigens genes such as those encoding the
251 toxic shock syndrome toxin (*tst*) and the exfoliative toxin (*eta*) were found in a small
252 number of strains independently of the source, while the *pvl-M/F* gene, implicated in the
253 damage of host defense cell membranes, was present in four bovine strains. The
254 important role of these toxins in bovine mastitis has been previously reported and the
255 presence of the leukocidin M/F variant has been described as characteristic of bovine *S.*
256 *aureus* strains (Fueyo *et al.*, 2005; Yamada *et al.*, 2005; Monecke *et al.*, 2007). When
257 bacterial strains from clinical and non clinical origin were compared, presence of *sirB*
258 gene (encoding an iron-siderophore transporter) was found to be associated to strains
259 isolated from cases of infectious mastitis independently of their human or bovine origin
260 (Fisher's exact test, $P = 0.008$).
261

262 **Antibiotic resistance.** Regardless of their origin, all the strains were sensitive to
263 gentamicin ($\leq 2 \mu\text{g ml}^{-1}$), tetracycline ($\leq 4 \mu\text{g ml}^{-1}$), nitrofurantoin ($\leq 32 \mu\text{g ml}^{-1}$),
264 mupirocin ($\leq 4 \mu\text{g ml}^{-1}$), streptomycin ($\leq 1,000 \mu\text{g ml}^{-1}$), clindamycin ($\leq 0.5 \mu\text{g ml}^{-1}$),
265 imipenem ($\leq 0.12 \mu\text{g ml}^{-1}$), rifampin ($\leq 1 \mu\text{g ml}^{-1}$), trimethoprim/sulfamethoxazole
266 ($\leq 1/38 \mu\text{g ml}^{-1}$), fosfomycin ($\leq 16 \mu\text{g ml}^{-1}$) and teicoplanin ($\leq 0.5 \mu\text{g ml}^{-1}$). Most of the
267 strains from cow's bulk tank milk and healthy women were susceptible to the lowest
268 concentration of most antibiotics (data not shown). All strains recovered from mastitis
269 infections were susceptible to oxacillin, ciprofloxacin, vancomycin and
270 quinupristin/dalfopristin according to the breakpoints established by the Clinical and
271 Laboratory Standards Institute (CLSI, 2010). In general, strains involved in human
272 mastitis showed higher MICs than isolates from bovine mastitis, with intermediate
273 resistances observed for some antibiotics (such as chloramphenicol and erythromycin)
274 among the strains involved in human mastitis (Table 3). A significant difference was
275 detected for penicillin resistance between isolates from human and bovine cases of
276 infectious mastitis (Fisher's exact test, $P = 0.020$). Three out of the 10 strains recovered
277 from bovine mastitis were ampicillin resistant, in contrast to seven out of 10 obtained
278 from human mastitic milk, even though the difference was not statistically significant
279 (Fisher's exact test, $P = 0.101$). In concordance with these results, the *mecA* gene was
280 not detected among the mastitis-related strains and the presence of the *blaZ* gene was
281 higher among the human isolates from mastitic milk (Fisher's exact test, $P = 0.057$).
282 This enhanced antibiotic resistance of human *S. aureus* has been previously described
283 (Reinoso *et al.*, 2008) and might be a consequence of higher antibiotic pressure in
284 human hosts.

285

286 **Hemolysis.** All the non-infectious strains displayed a non hemolytic behaviour on
287 sheep blood agar plates. In contrast, most of the isolates from bovine mastitis cases
288 (8/10) showed a complete lysis of the red blood cells surrounding the colony causing a
289 clearing of the blood from the medium, while only four of the strains from human
290 mastitis presented this type of hemolysis (Table 4). However, this difference was not
291 statistically significant (Fisher's exact test, $P = 0.170$). Strains of *S. aureus* from bovine
292 milk typically produce β -hemolysin (Larsen *et al.*, 2002; Monecke *et al.*, 2007), while
293 many human isolates have β -hemolysin-converting bacteriophages inserted in the *hly*
294 gene (van Wamel *et al.*, 2006). Although α -, β -, and δ -hemolysins are relevant in
295 several infections caused by *S. aureus*, the pathogenic significance of such toxins in
296 human disease has not yet been fully established (Iwatsuki *et al.*, 2006). Some authors
297 have reported the ubiquitous nature of some of these hemolysins (like the α -hemolysin
298 encoded by *hly* gene) regardless of the strain source (Peacock *et al.*, 2002).

299

300 **Slime and biofilm production.** Slime production was a relatively frequent
301 phenotype among the mastitis-associated strains, with 12 out of the 20 strains positive
302 in the Congo Red Agar assay (Table 4) in contrast with only three out 10 non-infectious
303 strains. However this difference was not statistically different (Fisher's exact test, $P =$
304 0.245). In parallel, the potential for biofilm production was determined by a quantitative
305 assay using microtiter plates and the results are shown in Table 4. Globally, the
306 adhesion to polystyrene plates was low when compared with a positive control
307 ($OD_{570} \sim 1$) in spite of the fact that all of them contained the gene *icaA*. There was not a
308 statistically significant difference in the ability to form biofilm *in vitro* between the
309 strains associated to bovine and human mastitis (Kruskal Wallis test, $P = 0.070$).
310 Biofilm formation has been described in many cases of mastitis caused by *S. aureus*

311 (Melchior *et al.*, 2006; Oliveira *et al.*, 2006) but the phenotypic expression of this
312 property can be influenced by numerous factors such as the method, or the growth
313 media and conditions used in the assay. Discrepancies between slime production,
314 biofilm formation *in vitro*, and the presence of the *ica* gene have been previously
315 reported in bovine *S. aureus* (Vasudevan *et al.*, 2003).

316

317 **Presence of prophages.** The incidence of lysogenic strains was investigated since
318 many genes associated with virulence factors in *S. aureus* can be encoded by mobile
319 genetic elements such as bacteriophages. Lysogeny was observed only in two of the 10
320 strains isolated from human milk supplied by women with mastitis and in one strain
321 from milk of a healthy woman (Table 4). In contrast, phages were detected in most
322 strains from bovine origin, with the exception of strain SA1 isolated from bovine
323 mastitis and strain GDC3 from bulk tank milk. Globally, lysogeny was associated more
324 frequently to bovine than to human mastitis-causing strains (Fisher's exact test, $P =$
325 0.006). Some authors have proposed that lysogenization of a strain with phages carrying
326 *pvl* genes may transform a non-virulent strain into a pathogenic one (Melles *et al.*, 2004;
327 Yamada *et al.*, 2005). In this study, positive isolates for the long-known Pantone-
328 Valentine leukocidin gene (*pvl-S/F*) were not detected but presence of the more recently
329 described leukocidin M/F-PV like gene (*pvl-M/F*) was revealed in three of the lysogenic
330 strains isolated from bovine mastitis infections. This gene was originally described on a
331 prophage (ϕ PV-83) and has been associated frequently with mastitis-causing strains in
332 different ruminants (Rainard *et al.*, 2003; Yamada *et al.*, 2005; Monecke *et al.*, 2007),.
333

334 **Siderophore production.** Another potential pathogenic trait investigated was the
335 production of siderophores because the ability to acquire iron from the host by bacterial

336 siderophores may facilitate the establishment of infection. Different siderophores have
337 been characterized in *S. aureus* including iron-uptake ABC transporters (Dale *et al.*,
338 2004). The production of siderophores was highly variable among the strains tested
339 (Table 4), but it was significantly higher in the strains involved in mastitis than in the
340 non-infectious group (Kruskal Wallis test, $P = 0.039$). In concordance with this result,
341 the presence of *sirB* gene (encoding an iron-siderophore transporter) was also found to
342 be associated to mastitis-causing strains (Fisher's exact test, $P = 0.008$).

343 No clear association could be observed between the strains from human and bovine
344 mastitis studied, except for siderophore production. In fact, some properties of the
345 strains seemed to depend on their source. The human mastitis strains were characterized
346 by a higher resistance to antibiotics, specifically to β -lactams. Although the small
347 sample size is a clear limitation of this work, and further studies involving a larger
348 number of strains will be required to confirm these results, this is the first time, to our
349 knowledge, that *S. aureus* involved in human lactational mastitis have been examined in
350 detail. High genetic diversity was found among these strains and two novel sequence
351 types (ST1597 and ST1598) were registered.

352

353 **Acknowledgments**

354 This study was partly supported by the FUN-C-FOOD (Consolider-Ingenio 2010)
355 and AGL2010-15420 projects from the Ministerio de Educación y Ciencia (Spain). S.
356 Delgado was the recipient of a postdoctoral fellowship from the same Ministry. This
357 publication made use of the Multi Locus Sequence Typing website (<http://www.mlst.net>)
358 at Imperial College London developed by David Aanensen and funded by the Wellcome
359 Trust.

360

361 **References**

- 362 Aires de Sousa M, Parente CESR, Vieira-da-Motta O, Bonna ICF, Silva DA &
363 Lencastre H (2007) Characterization of *Staphylococcus aureus* isolates from buffalo,
364 bovine, ovine, and caprine milk samples collected in Rio de Janeiro state, Brazil.
365 *Appl Environ Microbiol* **73**: 3845–3849.
- 366 Anderson KL & Lyman RL (2006) Long-term persistence of specific genetic types of
367 mastitis-causing *Staphylococcus aureus* on three dairies. *J Dairy Sci* **89**: 4551–4556.
- 368 Casey AL, Lambert PA & Elliott TSJ (2007) Staphylococci. *Int J Antimicrob Agents* **29**:
369 S23–S32.
- 370 CLSI (Clinical and Laboratory Standards Institute) (2010) Performance standards for
371 antimicrobial susceptibility testing; twentieth informational supplement. M100-S20,
372 Vol. 30, No. 1. Wayne PA, USA.
- 373 Dale SE, Sebulsky MT & Heinrichs DE (2004) Involvement of *SirABC* in iron-
374 siderophore import in *Staphylococcus aureus*. *J Bacteriol* **186**: 8356-8362.
- 375 Delgado S, Arroyo R, Martín R & Rodríguez JM (2008) PCR-DGGE assessment of the
376 bacterial diversity of breast milk in women with lactational infectious mastitis. *BMC*
377 *Infect Dis* **8**: 51.
- 378 Delgado S, Arroyo R, Jiménez E, Marín ML, del Campo R, Fernández L & Rodríguez
379 JM (2009) *Staphylococcus epidermidis* strains isolated from breast milk of women
380 suffering infectious mastitis: potential virulence traits and resistance to antibiotics.
381 *BMC Microbiol* **9**: 82.
- 382 Enright MC, Day NP, Davies CE, Peacock SJ & Spratt BG (2000) Multilocus sequence
383 typing for characterization of methicillin-resistant and methicillin-susceptible clones
384 of *Staphylococcus aureus*. *J Clin Microbiol* **38**: 1008-1015.

385 Foxman B, D'Arcy H, Gillespie B, Bobo JK & Schwartz K (2002) Lactation mastitis:
386 occurrence and medical management among 946 breastfeeding women in the United
387 States. *Am J Epidemiol* **155**: 103-114.

388 Freeman DJ, Falkiner F & Keane CT (1989) New method for detecting slime
389 production by coagulase negative staphylococci. *J Clin Pathol* **42**: 872-874.

390 Freney J, Kloos WE, Hajek V, Webster JA, Bes M, Brun Y & Vernozy-Rozand C (1999)
391 Recommended minimal standards for description of new staphylococcal species.
392 Subcommittee on the taxonomy of staphylococci and streptococci of the
393 International Committee on Systematic Bacteriology. *Int J Syst Bacteriol* **49**: 489-
394 502.

395 Fueyo JM, Mendoza MC, Rodicio MR, Muñiz J, Álvarez MA & Martín MC (2005)
396 Cytotoxin and pyrogenic toxin superantigen gene profiles of *Staphylococcus aureus*
397 associated with subclinical mastitis in dairy cows and relationship with
398 macrorestriction genomic profiles. *J Clin Microbiol* **43**: 1278-1284.

399 García P, Madera C, Martínez B, Rodríguez A & Suárez JE (2009). Prevalence of
400 bacteriophages infecting *Staphylococcus aureus* in dairy samples and their potential
401 as biocontrol agents. *J Dairy Sci* **92**: 3019-3026.

402 Herron-Olson L, Fitzgerald JR, Musser JM & Kapur V (2007) Molecular correlates of
403 host specialization in *Staphylococcus aureus*. *PLoS One* **10**: e1120.

404 Iwatsuki K, Yamasaki O, Morizane S & Oono T (2006) Staphylococcal cutaneous
405 infections: invasion, evasion and aggression. *J Dermatol Sci* **42**: 203-214.

406 Jarraud S, Mougel C, Thioulouse J, Lina G, Meugnier H, Forey F, Nesme X, Etienne J
407 & Vandenesch F (2002) Relationships between *Staphylococcus aureus* genetic
408 background, virulence factors, *agr* groups (alleles), and human disease. *Infect Immun*
409 **70**: 631-641.

410 Jiménez E, Delgado S, Maldonado A, Arroyo R, Albújar M, García N, Jarrod M,
411 Fernández L, Gómez A & Rodríguez JM (2008) *Staphylococcus epidermidis*: a
412 differential trait of the fecal microbiota of breast-fed infants. *BMC Microbiol* **8**: 143.

413 Kozytska S, Stauss D, Pawlik MC, Hensen S, Eckart M, Ziebuhr W, Witte W & Ohlsen
414 K (2010) Identification of specific genes in *Staphylococcus aureus* strains associated
415 with bovine mastitis. *Vet Microbiol* **145**: 360-365.

416 Kullen MJ, Sanozky-Dawes RB, Crowell DC & Klaenhammer TR (2000) Use of the
417 DNA sequence of variable regions of the 16S rRNA gene for rapid and accurate
418 identification of bacteria in the *Lactobacillus acidophilus* complex. *J Appl Microbiol*
419 **89**: 511-516.

420 Larsen HD, Aarestrup FM & Jensen NE (2002) Geographical variation in the presence
421 of genes encoding superantigenic exotoxins and beta-hemolysin among
422 *Staphylococcus aureus* isolated from bovine mastitis in Europe and USA. *Vet*
423 *Microbiol* **85**: 61-67.

424 Martín MC, González-Hevia MA & Mendoza MC (2003) Usefulness of a two-step PCR
425 procedure for detection and identification of enterotoxigenic staphylococci of
426 bacterial isolates and food samples. *Food Microbiol* **20**: 605-610.

427 Martineau F, Picard FJ, Lansac N, Ménard C, Roy PH, Ouellette M & Bergeron MG
428 (2000) Correlation between the resistance genotype determined by multiplex PCR
429 assays and the antibiotic susceptibility patterns of *Staphylococcus aureus* and
430 *Staphylococcus epidermidis*. *Antimicrob Agents Chemother* **44**: 231-238.

431 Martineau F, Picard FJ, Ke D, Paradis S, Roy PH, Ouellette M & Bergeron MG (2001)
432 Development of a PCR assay for identification of staphylococci at genus and species
433 levels. *J Clin Microbiol* **39**: 2541-2547.

434 Massonet C, Pintens V, Merckx R, Anné J, Lammertyn E & Van Eldere J (2006) Effect
435 of iron on the expression of *sirR* and *sitABC* in biofilm-associated *Staphylococcus*
436 *epidermidis*. *BMC Microbiol* **6**: 103.

437 Mehrotra M, Wang G & Johnson WM (2000) Multiplex PCR for detection of genes for
438 *Staphylococcus aureus* enterotoxins, exfoliative toxins, toxic shock syndrome toxin 1,
439 and methicillin resistance. *J Clin Microbiol* **38**: 1032-1035.

440 Melchior MB, Vaarkamp H & Fink-Gremmels J (2006) Biofilms: a role in recurrent
441 mastitis infections? *Vet J* **171**: 398-407.

442 Melles DC, Gorkink RF, Boelens HA, *et al.* (2004) Natural population dynamics and
443 expansion of pathogenic clones of *Staphylococcus aureus*. *J Clin Invest* **114**: 1732-
444 1740.

445 Monecke S, Kuhnert P, Hotzel H, Slickers P & Ehricht R (2007) Microarray based
446 study on virulence-associated genes and resistance determinants of *Staphylococcus*
447 *aureus* isolates from cattle. *Vet Microbiol* **125**: 128–140.

448 Mørk T, Tollersrud T, Kvitle B, Jørgensen HJ & Waage S (2005) Comparison of
449 *Staphylococcus aureus* genotypes recovered from cases of bovine, ovine, and caprine
450 mastitis. *J Clin Microbiol* **43**: 3979-3984.

451 Murchan S, Kaufmann ME, Deplano A, *et al.* (2003) Harmonization of pulsed-field
452 electrophoresis protocols for epidemiological typing of strains of methicillin-resistant
453 *Staphylococcus aureus*: a single approach developed by consensus in 10 European
454 laboratories and its application for tracing the spread of related strains. *J Clin*
455 *Microbiol* **41**: 1574-1585.

456 Oliveira M, Bexiga R, Nunes SF, Carneiro C, Cavaco LM, Bernardo F & Vilela CL
457 (2006) Biofilm-forming ability profiling of *Staphylococcus aureus* and
458 *Staphylococcus epidermidis* mastitis isolates. *Vet Microbiol* **118**: 133-140.

459 Peacock SJ, Moore CE, Justice A, Kantzanou M, Story L, Mackie K, O'Neill G & Day
460 NPJ (2002) Virulent combinations of adhesion and toxin genes in natural populations
461 of *Staphylococcus aureus*. *Infect Immun* **70**: 4987-4996.

462 Rabello RF, Moreira BM, Lopes RM, Teixeira LM, Riley LW & Castro AC (2007)
463 Multilocus sequence typing of *Staphylococcus aureus* isolates recovered from cows
464 with mastitis in Brazilian dairy herds. *J Med Microbiol* **56**: 1505-1511.

465 Rainard P, Corrales JC, Barrio MB, Cochard T & Poutrel B (2003) Leucotoxic activities
466 of *Staphylococcus aureus* strains isolated from cows, ewes, and goats with mastitis:
467 importance of LukM/LukF'-PV leukotoxin. *Clin Diagn Lab Immunol* **10**: 272-277.

468 Reinoso EB, El-Sayed A, Lämmler C, Bogni C & Zschöck M (2008) Genotyping of
469 *Staphylococcus aureus* isolated from humans, bovine subclinical mastitis and food
470 samples in Argentina. *Microbiol Res* **163**: 314-322.

471 Riordan JM & Nichols FH (1990) A descriptive study of lactation mastitis in long-term
472 breastfeeding women. *J Human Lact* **6**: 53-58.

473 Sakwinska O, Kuhn G, Balmelli C, Francioli P, Giddey M, Perreten V, Riesen A,
474 Zysset F, Blanc DS & Moreillon P (2009). Genetic diversity and ecological success
475 of *Staphylococcus aureus* strains colonizing humans. *Appl Environ Microbiol* **75**:
476 175-183.

477 Sambrook J, Fritsch EF & Maniatis T (1989) *Molecular Cloning: a Laboratory Manual*.
478 Cold Spring Harbor, New York.

479 Schwyn B & Neilands JB (1987) Universal chemical assay for the detection and
480 determination of siderophores. *Anal Biochem* **160**: 47-56.

481 Smith EM, Green LE, Medley GF, Bird HE, Fox LK, Schukken YH, Kruze JV, Bradley
482 AJ, Zadoks RN & Dowson CG (2005) Multilocus sequence typing of

483 intercontinental bovine *Staphylococcus aureus* isolates. *J Clin Microbiol* **43**: 4737-
484 4743.

485 Sung JM, Lloyd DH & Lindsay JA (2008) *Staphylococcus aureus* host specificity:
486 comparative genomics of human versus animal isolates by multi-strain microarray.
487 *Microbiology* **154**: 1949-1959.

488 Thomsen AC, Hansen KB & Møller BR (1983) Leukocyte counts and microbiologic
489 cultivation in the diagnosis of puerperal mastitis. *Am J Obstet Gynecol* **146**: 938-941.

490 van Leeuwen WB, Melles DC, Alaidan A et al. (2005). Host-and tissue-specific
491 pathogenic traits of *Staphylococcus aureus*. *J Bacteriol* **187**: 4584-4591.

492 van Wamel WJ, Rooijackers SH, Ruyken M, van Kessel KP & van Strijp JA (2006).
493 The innate immune modulators staphylococcal complement inhibitor and chemotaxis
494 inhibitory protein of *Staphylococcus aureus* are located on beta-hemolysin-
495 converting bacteriophages. *J Bacteriol* **188**: 1310-1315.

496 Vasudevan P, Nair MKM, Annamalai T & Venkitanarayanan KS (2003) Phenotypic
497 and genotypic characterization of bovine mastitis isolates of *Staphylococcus aureus*
498 for biofilm formation. *Vet Microbiol* **92**: 179-185.

499 Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA &
500 Nouwen JL (2005) The role of nasal carriage in *Staphylococcus aureus* infections.
501 *Lancet Infect Dis* **5**: 751-762.

502 World Health Organization, WHO (2000) Mastitis: Causes and Management,
503 WHO/FCH/CAH/00.13. Department of child and adolescent health and development,
504 Geneva.

505 Yamada T, Tochimarun N, Nakasuji S, Hata E, Kobayashi H, Eguchi M, Kaneko J,
506 Kamio Y, Kaidoh T & Takeuchi S (2005) Leukotoxin family genes in

507 *Staphylococcus aureus* isolated from domestic animals and prevalence of *lukM-lukF-*
508 *PV* genes by bacteriophages in bovine isolates. *Vet Microbiol* **110**: 97-103.

509 Zadoks R, van Leeuwen W, Barkema H, Sampimon O, Verbrugh H, Schukken YH &
510 van Belkum A (2000) Application of pulsed-field gel electrophoresis and binary
511 typing as tools in veterinary clinical microbiology and molecular epidemiologic
512 analysis of bovine and human *Staphylococcus aureus* isolates. *J Clin Microbiol* **38**:
513 1931–1939.

514

515 **Figure legends**

516

517 **Fig. 1.** Dendrogram obtained after clustering analysis of pulsed field gel electrophoresis
518 profiles of the *Staphylococcus aureus* strains included in this study. Multilocus
519 sequence typing results, including sequence types (STs) and clonal complexes (CCs),
520 are also shown.

521

522 **Fig. 2.** Multiplex PCR assays for the simultaneous detection of the genes encoding
523 different hemolysins (a) and adhesins (b). (a) M₁, molecular weight marker (DNA
524 HyperLadder II, Bioline, London, UK); Lanes: 1, *Staphylococcus aureus* ACLI1; 2, *S.*
525 *aureus* BALD1; 3, *S. aureus* SA2; 4, *S. aureus* SA15; 5, *S. aureus* LX153b. *hlg* gene:
526 535 bp; *hlb* gene: 309 bp; *hla* gene: 209 bp; *hld* gene: 111 bp. (b) M₂, molecular weight
527 marker (DNA HyperLadder I, Bioline); Lanes: 1, *S. aureus* SA10; 2, *S. aureus* O2LI2; 3,
528 *S. aureus* BALD1. *clfA* gene: 1,548 bp; *fnbA* gene: 1,226 bp; *sdrE* gene: 749 bp; *ebpS*
529 gene: 506 bp.

1 **Table 1.** Primers and PCR conditions used in this study

Gene	Product	Primers sequence (5'–3')	Amplicon size	Annealing temperature	Control strain	Reference
<i>eta</i>	Exfoliative toxin A	Fw: GCAGGTGTTGATTTAGCATT Rv: AGATGTCCCTATTTTTGCTG	100 bp	58 °C	Isolate Z2LD1	van Leeuwen <i>et al.</i> 2005
<i>hla</i>	α -hemolysin	Fw: CTGATTACTATCCAAGAAATTCGATTG Rv: CTTTCCAGCCTACTTTTTTATCAGT	209 bp	58 °C ^a	CETC 976	Jarraud <i>et al.</i> 2002
<i>hlb</i>	β -hemolysin	Fw: GTGCACTTACTGACAATAGTGC Rv: GTTGATGAGTAGCTACCTTCAG	309 bp	58 °C ^a	CETC 976	Jarraud <i>et al.</i> 2002
<i>hlg</i>	γ -hemolysin	Fw: GTCAYAGAGTCCATAATGCATTTAA Rv: CACCAAATGTATAGCCTAAAGTG	535 bp	58 °C ^a	CECT 435	Jarraud <i>et al.</i> 2002
<i>hld</i>	δ -hemolysin	Fw: AAGAATTTTTATCTTAATTAAGGAAGGAGTG Rv: TTAGTGAATTTGTTCACTGTGTCGA	111 bp	58 °C ^a	CETC 976	Jarraud <i>et al.</i> 2002
<i>tst</i>	Toxic shock syndrome toxin	Fw: AAGCCCTTTGTTGCTTGCG Rv: ATCGAACTTTGGCCCACTTTT	404 bp	62 °C	CETC 957	van Leeuwen <i>et al.</i> 2005
<i>pvl-S/F</i>	Panton-Valentin leukocidin (component S and F)	Fw: ATCATTAGGTAAAATGTCTGGACATGATCCA Rv: GCATCAASTGTATTGGATAGCAAAAGC	433 bp	65 °C	CECT 435	Jarraud <i>et al.</i> 2002
<i>pvl-M/F</i>	Panton-Valentin leukocidin (component M and F)	Fw: AACTTTCAATGATGTTAAACAAAATAGAG Rv: AAAATAGTCTCTAGCATTAGGTCC	405 bp	57 °C	CETC 957	Yamada <i>et al.</i> 2005
<i>se-adej</i>	Enterotoxins SEs	Fw: AAAGATTTGCGAAAAAAGTGTGAATT Rv: TTKYRTATAAATABAWRTCAATATG	669 bp	50 °C	CECT 4439	Martín <i>et al.</i> 2003
<i>fnbA</i>	Adhesin for fibronectin	Fw: CACAACCAGCAAATATAG Rv: CTGTGTGGTAATCAATGTC	1,226 bp	50 °C ^b	CETC 976	van Leeuwen <i>et al.</i> 2005
<i>cna</i>	Adhesin for collagen	Fw: AGTGGTTACTAATCATG Rv: CAGGATAGATTGGTTTA	1,722 bp	45 °C	CETC 976	van Leeuwen <i>et al.</i> , 2005
<i>clfA</i>	Adhesin for fibrinogen	Fw: GTAGGTACGTTAATCGGTT Rv: CTCATCAGGTTGTTCAAGG	1,548 bp	50 °C ^b	CETC 976	van Leeuwen <i>et al.</i> 2005
<i>sdrE</i>	Putative adhesin	Fw: CAGTAAATGTGTCAAAAAGA Rv: TTGACTACCAGCTATATC	749 bp	50 °C ^b	CETC 976	Peacock <i>et al.</i> 2002
<i>ebpS</i>	Adhesin for elastin	Fw: CAATCGATAGACACAAATTC Rv: CAGTTACATCATCATGTTTA	506 bp	50 °C ^b	CETC 976	Peacock <i>et al.</i> 2002
<i>icaA</i>	Polysaccharide intercellular adhesin	Fw: GATTATGTAATGTGCTTGGA Rv: ACTACTGCTGCGTTAATAAT	770 bp	50 °C	CETC 976	Peacock <i>et al.</i> 2002
<i>mecA</i>	Methicillin resistance	Fw: GGTCCCATTA ACTCTGAAG Rv: AGTTCTGCAGTACCGGATTTTGC	163 bp	57 °C	CECT 4439	Mehrotra <i>et al.</i> 2000
<i>blaZ</i>	β -lactamase	Fw: ACTTCAACACCTGCTGCTTTC Rv: TGACCACTTTTATCAGCAACC	173 bp	61 °C	CETC 976	Martineau <i>et al.</i> 2000
<i>sirB</i>	Iron-siderophore transporter	Fw: CAGCTACGGCTACCGAAATA Rv: CATTTTTGGGGGCTATTGTTGT	399 bp	61 °C	CECT 976	Dale <i>et al.</i> 2004

^{a, b} primers used in the same multiplex PCR reaction

2

1 **Table 2.** Presence of putative virulence genes in the *S. aureus* isolates

Virulence determinant	Mastitis		<i>P</i> -value ^a	Non-infectious		<i>P</i> -value ^b
	Human (n=10)	Bovine (n=10)		Human (n=5)	Bulk tank (n=5)	
Adhesins						
<i>fnbA</i>	10	10	—	5	5	—
<i>cna</i>	5	10	0.033	3	2	0.231
<i>clfA</i>	10	10	—	5	5	—
<i>sdrE</i>	6	7	>0.99	2	3	0.694
<i>ebpS</i>	9	9	>0.99	5	5	0.540
Toxins						
<i>eta</i>	1	0	>0.99	0	0	>0.99
<i>hla</i>	10	10	—	5	5	—
<i>hlb</i>	1	8	0.006	2	4	0.700
<i>hlg</i>	3	0	0.211	3	1	0.181
<i>hld</i>	10	10	—	5	5	—
<i>tst</i>	1	1	>0.99	1	1	0.584
<i>pvl-S/F</i>	0	0	—	0	0	—
<i>pvl-M/F</i>	0	3	0.211	0	1	>0.99
<i>se-adej</i>	0	0	—	0	0	—
Others						
<i>icaA</i>	10	10	—	5	5	—
<i>mecA</i>	0	0	—	2	0	0.103
<i>blaZ</i>	9	4	0.057	4	2	>0.99
<i>sirB</i>	10	10	—	2	4	0.008

2 ^a Fisher's exact test to compare the presence of the virulence determinant in strains from human and bovine
3 mastitis infections

4 ^b Fisher's exact test to compare the presence of the virulence determinant in mastitis isolates and non-infectious
5 strains
6

1 **Table 3.** Antibiotic susceptibility of *S. aureus* isolated from human and bovine mastitis cases
 2 according to the microbiological breakpoints (MICs) defined by the Clinical and Laboratory
 3 Standards Institute (CLSI)

Antibiotic ^a	Sample origin	Number of resistant (R), intermediate (I) and susceptible (S) strains according to MICs breakpoints ($\mu\text{g ml}^{-1}$) established by the CLSI (2010)		
PEN		R (≥ 0.25)^b		S (≤ 0.12)
	Human	9		1
	Bovine	3		7
AMP		R (≥ 0.5)		S (≤ 0.25)
	Human	7		3
	Bovine	3		7
OXA		R (≥ 4)		S (≤ 2)
	Human			10
	Bovine			10
CIP		R (≥ 4)	I (2)	S (≤ 1)
	Human			10
	Bovine			10
CHL		R (≥ 32)	I (16)	S (≤ 8)
	Human	1	6	3
	Bovine	1		9
ERY		R (≥ 8)	I (1-4)	S (≤ 0.5)
	Human		4	6
	Bovine			10
VAN		R (≥ 16)	I (4-8)	S (≤ 2)
	Human			10
	Bovine			10
LNZ		R (≥ 8)		S (≤ 4)
	Human	1		9
	Bovine			10
Q/D		R (≥ 4)	I (2)	S (≤ 1)
	Human			10
	Bovine			10

4 ^a PEN: penicillin; AMP: ampicillin; OXA: oxacillin; CIP: ciprofloxacin; CHL: chloramphenicol; ERY:
 5 erythromycin; VAN: vancomycin; LNZ: linezolid; Q/D: quinupristin/dalfopristin

6 ^b Bold indicates significant differences in the number of resistant strains from human and bovine mastitis
 7 infections (Fisher's exact test, $P = 0.020$)
 8


1 **Table 4.** Phenotypic traits of the *S. aureus* isolates


Strains	Phenotypic traits				
	Hemolysis	Slime	Biofilm (OD ₅₇₀)	Siderophores ^a (%)	Prophages ^c
Mastitis					
Human					
OD111	+	+	0.962	45.4	+
S3B	+	+	0.953	30.9	-
ACLI1	-	+	0.151	46.0	-
S1LI12	-	+	0.138	45.8	-
DH3a	-	+	0.155	33.5	-
DI2e	+	-	0.068	47.7	+
BALD1	-	-	0.115	33.8	-
O2LI2	+	+	0.797	27.5	-
Z2LD1	-	+	0.387	29.8	-
AXLI12	-	+	0.140	50.6	-
Bovine					
SA1	+	+	0.175	59.3	-
SA3	+	+	0.421	25.4	+
SA4	+	-	0.086	26.3	+
SA5	-	-	0.077	49.8	+
SA8	-	-	0.081	36.8	+
SA10	+	+	0.095	32.0	+
SA11	+	+	0.067	37.7	+
SA14	+	-	0.099	55.5	+
SA15	+	-	0.240	58.9	+
SA16	+	-	0.136	48.3	+
Non-infectious					
Human					
LC001	-	-	0.143	34.7	-
LG5081	-	+	0.168	24.4 ^b	+
LX153b	-	-	0.087	31.3	-
L1741	-	-	0.169	29.2 ^b	-
L1744	-	-	0.046	31.5 ^b	-
Bulk tank					
GDC3	-	-	0.116	24.1 ^b	-
GDC6	-	-	0.418	40.5	+
AC11	-	+	0.904	32.7	+
JFL2	-	+	0.517	28.6	+
GRA16	-	-	0.319	47.4	+

2 ^a Siderophore production in mastitis strains differed significantly from non-infectious strains (Kruskal-
3 Wallis test, $P=0.039$)


4 ^b No *sirB* gen was detected.

5 ^c Presence of prophages in bovine mastitis strains differed significantly from human mastitis strains (Fisher's
6 exact test, $P=0.006$)





(a)



(b)